Global Chronic Kidney Disease Drug Market, By Drug Class (ACE Inhibitors, B-Blockers, Calcium Channel Blockers, Diuretics, Erythropoiesis-Stimulating Agents (ESAs) and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and By Geography (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa) - Trends, Analysis and Forecast till 2029

Chronic kidney disease or chronic kidney failure is fatal condition, associated with gradual loss of kidney function, over the period of time. Chronic kidney condition will get worse, if the damaged kidney have not been diagnosed and treated. In the early stages of chronic kidney disease, patient may observe certain sign or symptoms. However, chronic kidney can progress to end-stage kidney failure, which is fatal and only be treated with dialysis (artificial filtering) or kidney transplant. 

Treatment for chronic kidney disease is focus on slowing the progression of kidney damage, depending on the underlying cause of kidney dysfunction. Various factors leading to increase the risk of chronic kidney disease includes high blood pressure, diabetes, obesity, and smoking, among others. Management of chronic kidney disease involves managing the co-morbidities such as blood pressure, treatment regimen to lower the cholesterol in diabetes medications and anemia treatment. Increasing prevalence of high blood pressure, obesity and diabetes leading to cause chronic kidney disease among the patients, is expected to drive the growth of chronic kidney disease drug market. 

The global chronic kidney disease drug market has been segmented on the basis of drug class, distribution channel and region.

On the basis of drug class, the chronic kidney disease drug market is segmented into ACE inhibitors, B-blockers, calcium channel blockers, diuretics, erythropoiesis-stimulating agents (ESAs), and others. Further, the distribution channel for chronic kidney disease drug market includes hospital pharmacies, retail pharmacies and online pharmacies. 

On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the chronic kidney disease drug market. Factors responsible for the growth of market includes substantial rise in the awareness among the people regarding the risk of chronic kidney failure. Initiatives taken by key players in the market and government agencies in educating the people regarding possible risk factors associated with gradual loss of kidney function is expected to boost the market growth over the forecast period.

The key players operating in the global chronic kidney disease drug market includes Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., GlaxoSmithKline plc, and Keryx Biopharmaceuticals Inc.

Research Objective and Assumption

• Preface
• Research Objectives
• Study Scope
• Years Considered for the study
• Assumptions
• Abbreviations

Research Methodology

• Research data
• Primary Data
  • Primary Interviews
  • Primary Breakdown
  • Key data from Primary Sources
  • Key Thickness Insights
• Secondary Data
  • Major Secondary Sources
  • Secondary Sources
• Market Estimation
• Top-Down Approach
  • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
• Bottom-Up Approach
  • Approach for estimating market share by Bottom-up Analysis (Demand Side)
• Market Breakdown and Data Triangulation
• Research Assumptions

Market Preview

• Executive Summary
• Key Findings—Global Outlook for medical carts Strategies
  • Key Questions this Study will Answer
  • Market Snippet, By Drug Class
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Opportunity Map Analysis
• Executive Summary—3 Big Predictions

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restrains
  • Market Opportunities
  • Market Trends
• DR Impact Analysis
• PEST Analysis
• Porter’s Five Forces Analysis
• Opportunity Orbit
• Market Investment Feasibility Index
• Macroeconomic Factor Analysis

Chronic Kidney Disease Drug Market, By Drug Class, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• ACE Inhibitors
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• B-Blockers
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Calcium Channel Blockers
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Diuretics
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Erythropoiesis-Stimulating Agents (ESAs)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Chronic Kidney Disease Drug Market, By Distribution Channel, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Hospital Pharmacy
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Retail Pharmacy
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Online Pharmacy
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Chronic Kidney Disease Drug Market, By Region, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • U.S.
    • Canada
• Europe
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • UK
    • France
    • Germany
    • Russia
    • Italy
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Latin America
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
• Brazil
• Mexico
• Rest of Latin America

 

• Middle East & Africa
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
• GCC
• Israel
• South Africa
• Rest of Middle East

Competitive Landscape

• Heat Map Analysis
• Market Presence and Specificity Analysis

Company Profiles

•  Amgen Inc
  •   Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
•  Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Pfizer Inc.
  •  Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• AstraZeneca plc
  •  Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• F. Hoffmann-La Roche Ltd
  •  Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Sanofi S.A
  •  Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Kissei Pharmaceutical Co. Ltd.
  •  Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• AbbVie Inc
  •  Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• GlaxoSmithKline plc
  •  Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Keryx Biopharmaceuticals Inc.
  •  Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

The Last Word

• Future Impact
• About Us
• Contact